Liliana L Berube BS , Kwang-ok P Nickel PhD , Mari Iida PhD , Sravani Ramisetty PhD , Prakash Kulkarni PhD , Ravi Salgia MD, PhD , Deric L Wheeler PhD , Randall J Kimple MD, PhD, MBA
{"title":"辐射敏感性:预测患者衍生癌症模型的兴起","authors":"Liliana L Berube BS , Kwang-ok P Nickel PhD , Mari Iida PhD , Sravani Ramisetty PhD , Prakash Kulkarni PhD , Ravi Salgia MD, PhD , Deric L Wheeler PhD , Randall J Kimple MD, PhD, MBA","doi":"10.1016/j.semradonc.2023.03.005","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Patient-derived cancer models have been used for decades to improve our understanding of cancer and test anticancer treatments. Advances in radiation delivery have made these models more attractive for studying </span>radiation sensitizers and understanding an individual patient's </span>radiation sensitivity<span><span>. Advances in the use of patient-derived cancer models lead to a more clinically relevant outcome, although many questions remain regarding the optimal use of patient-derived xenografts and patient-derived </span>spheroid<span> cultures. The use of patient-derived cancer models as personalized predictive avatars through mouse and zebrafish models is discussed, and the advantages and disadvantages of patient-derived spheroids are reviewed. In addition, the use of large repositories of patient-derived models to develop predictive algorithms to guide treatment selection is discussed. Finally, we review methods for establishing patient-derived models and identify key factors that influence their use as both avatars and models of cancer biology.</span></span></p></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"33 3","pages":"Pages 279-286"},"PeriodicalIF":2.6000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287034/pdf/","citationCount":"0","resultStr":"{\"title\":\"Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models\",\"authors\":\"Liliana L Berube BS , Kwang-ok P Nickel PhD , Mari Iida PhD , Sravani Ramisetty PhD , Prakash Kulkarni PhD , Ravi Salgia MD, PhD , Deric L Wheeler PhD , Randall J Kimple MD, PhD, MBA\",\"doi\":\"10.1016/j.semradonc.2023.03.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>Patient-derived cancer models have been used for decades to improve our understanding of cancer and test anticancer treatments. Advances in radiation delivery have made these models more attractive for studying </span>radiation sensitizers and understanding an individual patient's </span>radiation sensitivity<span><span>. Advances in the use of patient-derived cancer models lead to a more clinically relevant outcome, although many questions remain regarding the optimal use of patient-derived xenografts and patient-derived </span>spheroid<span> cultures. The use of patient-derived cancer models as personalized predictive avatars through mouse and zebrafish models is discussed, and the advantages and disadvantages of patient-derived spheroids are reviewed. In addition, the use of large repositories of patient-derived models to develop predictive algorithms to guide treatment selection is discussed. Finally, we review methods for establishing patient-derived models and identify key factors that influence their use as both avatars and models of cancer biology.</span></span></p></div>\",\"PeriodicalId\":49542,\"journal\":{\"name\":\"Seminars in Radiation Oncology\",\"volume\":\"33 3\",\"pages\":\"Pages 279-286\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287034/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S105342962300019X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S105342962300019X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models
Patient-derived cancer models have been used for decades to improve our understanding of cancer and test anticancer treatments. Advances in radiation delivery have made these models more attractive for studying radiation sensitizers and understanding an individual patient's radiation sensitivity. Advances in the use of patient-derived cancer models lead to a more clinically relevant outcome, although many questions remain regarding the optimal use of patient-derived xenografts and patient-derived spheroid cultures. The use of patient-derived cancer models as personalized predictive avatars through mouse and zebrafish models is discussed, and the advantages and disadvantages of patient-derived spheroids are reviewed. In addition, the use of large repositories of patient-derived models to develop predictive algorithms to guide treatment selection is discussed. Finally, we review methods for establishing patient-derived models and identify key factors that influence their use as both avatars and models of cancer biology.
期刊介绍:
Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.